Bruker Corporation

Bruker Corporation

BRKR
Bruker CorporationUS flagNASDAQ Global Select
59.56
USD
-0.36
- -
9.07BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
11.05
10.78
9.65
9.98
11.17
12.14
13.35
12.96
15.97
17.03
20.25
22.59
22.64
23.01
Basic EPS, GAAP
0.48
0.34
0.6
0.95
0.5
1.15
1.27
1.03
1.83
2
2.92
0.76
-0.15
-0.7
Free Cash Flow per Basic Share
0.57
0.48
1.16
0.58
0.7
1.22
0.9
1.53
1.26
0.98
1.66
0.91
0.09
0.62
Dividend per Share
- -
- -
- -
0.16
0.16
0.16
0.16
0.16
0.16
0.2
0.2
0.2
0.22
0.36
Book Value per Share
5.05
4.54
4.39
4.29
4.65
5.73
5.88
6.32
7.1
7.58
9.49
11.74
16.15
15.63
Tangible Book Value per Share
3.66
3.29
3.15
3.04
3.04
2.57
2.47
2.71
3.44
2.62
3.2
-4.21
0.06
0.55
Basic Weighted Avg Shares
166
168
168
161
158
156
155
153
151
149
146
149
152
152
Sales/Revenue/Turnover
1,839
1,809
1,624
1,611
1,766
1,896
2,073
1,988
2,418
2,531
2,964
3,366
3,436
3,500
Operating Margin (%)
9.28
7.46
9.86
12.88
13.53
14.63
14.73
13.45
17.64
18.27
16.5
11.26
6.87
7.6
Depreciation Expense
61
60
53
54
64
65
76
80
89
89
115
184
220
230
Net Income, GAAP
80
57
102
154
79
180
197
158
277
297
427
113
-9
-71
Effective Tax Rate (%)
34.35
41.16
18.05
13.01
59.4
26.03
29.39
28.52
28.71
28.12
21.63
44.18
133.18
66.84
Profit Margin (%)
4.35
3.13
6.26
9.53
4.45
9.48
9.51
7.94
11.46
11.72
14.41
3.36
-0.25
-2.03
Working Capital
783
784
677
751
834
705
1,151
1,133
1,533
1,199
962
772
933
1,020
LT Debt
354
354
265
392
416
323
860
889
1,264
1,235
1,235
2,181
1,991
1,815
Total Equity
850
772
733
693
734
928
938
974
1,085
1,132
1,413
1,815
2,510
2,436
Return on Invested Capital (%)
9.56
6.6
11.88
16.72
8.4
16.32
13.43
9.83
13.32
13.12
14.08
5.93
-1.77
- -
Return on Capital (%)
7.74
5.29
10.25
15.61
7.38
15.53
13.45
8.88
13
12.55
16.89
4.06
-0.67
2.37
Return on Common Equity (%)
10.32
7.03
13.62
21.75
11.13
22.16
21.87
16.9
27.28
27.16
34.3
7.16
-1.06
-5.11

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
52
8
10
LT Borrowings
1,852
1,663
1,815
LT Finance Leases
139
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
152
152
152
Market Capitalization
7,167
5,498
9,169

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,212
2,104
2,225
Cash, Cash Equivalents & STI
299
133
222
Accounts Receivable, Net
545
543
546
Inventories
1,095
1,122
1,120
Total Current Liabilities
1,279
1,355
1,205
Payables & Accruals
441
269
200
ST Debt
52
8
10
Deferred Revenue
441
480
445

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.91%
21.45%
38.29%
Free Cash Flow
-2.97%
-21.82%
-89.78%
Net Income, GAAP
6.63%
-10.89%
-107.6%
Sales/Revenue/Turnover
8.05%
11.82%
2.08%
Total Cash Common Dividend
- -
-2.84%
-37.09%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
722
801
864
980
3,366
2025
801
797
860
977
3,436
2026
823
838
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.05
0.27
0.09
0.76
2025
0.11
0.05
-0.41
0.1
-0.15
2026
0.02
-0.41
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.05
0.05
0.05
0.2
2025
0.05
0.05
- -
0.12
0.22
2026
0.12
0.12
- -
- -
- -

Company Description

CEO
Frank H. Laukien
Full Time Employees
11,085
Sector
Healthcare
Industry
Medical - Devices
Address
40 Manning Road Billerica MA United States of America 01821
IPO Date
Aug 4, 2000
Website
bruker.com
Business
Bruker Corporation (Nasdaq: BRKR) develops, manufactures, and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at molecular, cellular, and microscopic levels. The company offers a broad portfolio of products including nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) spectrometers; mass spectrometry systems; X-ray diffraction, scattering, and microscope analyzers; infrared, near-infrared, and Raman spectroscopy instruments; fluorescence and electron microscopy solutions; preclinical imaging systems; elemental analyzers; surface plasmon resonance systems; microbiology and clinical diagnostic tools such as ClinMASS and ClinDART kits; CBRNE detectors; semiconductor metrology equipment; and laboratory automation, data management, and test & measurement solutions. These products support applications in life science molecular research, pharmaceuticals, biotechnology, materials science, microscopy and nanoanalysis, industrial quality control, preclinical imaging, clinical phenomics and proteomics, and clinical microbiology. Founded in 1960 and headquartered in Billerica, Massachusetts, Bruker operates globally with over 11,000 employees across more than 90 locations on all continents, serving academic, governmental, pharmaceutical, biotechnology, and industrial customers. In April 2025, Bruker announced a majority investment in RECIPE Chemicals + Instruments GmbH, a Munich-based provider of clinical diagnostic assays, enhancing its small molecule diagnostics capabilities through integration of RECIPE's ClinMASS kits for EVOQ liquid chromatography triple-quadrupole mass spectrometers and upcoming high-throughput ClinDART kits for chromatography-free workflows on EVOQ-DART systems. Earlier, in 2024, the company acquired Dynamic Biosensors GmbH to strengthen its biosensor portfolio for molecular interaction analysis, complementing high-performance surface plasmon resonance systems like SPR #64 'Triceratops' for pharmaceutical and biotechnology drug discovery. Bruker also secured approximately $10 million in federally funded NMR system orders in October 2025 from institutions including the New York Structural Biology Center, University of Delaware, and Northwestern University, while initiating a major cost savings program targeting $100-120 million in annual reductions by fiscal 2026 amid market pressures.

Company News

  • Handelsbanken Fonder AB Acquires 18,165 Shares of Bruker Corporation $BRKR

  • Bruker Corporation $BRKR Shares Sold by Bank of America Corp DE

  • Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

  • Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

  • Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

  • Bruker Corporation (BRKR) Q2 2026 Earnings Call Transcript

  • Dow, S&P 500 Climb to Fresh Record Highs

  • Bruker (BRKR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

  • Bruker Q2 Earnings Call Highlights

  • Bruker (BRKR) Q2 Earnings Beat Estimates

  • Bruker Reports Second Quarter 2026 Financial Results

  • Bruker Reports Second Quarter 2026 Financial Results

  • Dimensional Fund Advisors LP Grows Position in Bruker Corporation $BRKR

  • Bruker Corp (BRKR) Stock Up 4.8% and Still Undervalued -- GF Score: 86/100

  • Bank of New York Mellon Corp Decreases Stake in Bruker Corporation $BRKR

  • First Trust Advisors LP Has $53.93 Million Holdings in Bruker Corporation $BRKR

  • California Public Employees Retirement System Sells 51,544 Shares of Bruker Corporation $BRKR

  • Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

  • A Look at Bruker Corp (BRKR) After 4.0% Gain -- GF Value $62.85 vs Price $62.15

  • Bruker Corporation $BRKR Shares Acquired by Fifth Third Bancorp